CapsoVision, Inc. (CV)
| Market Cap | 296.78M +60.2% |
| Revenue (ttm) | 13.89M +11.0% |
| Net Income | -29.83M |
| EPS | -0.62 |
| Shares Out | 50.05M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 83,034 |
| Open | 6.13 |
| Previous Close | 6.06 |
| Day's Range | 5.93 - 6.28 |
| 52-Week Range | 3.43 - 15.37 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About CV
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as a... [Read more]
Financial Performance
In 2025, CapsoVision's revenue was $13.55 million, an increase of 15.29% compared to the previous year's $11.76 million. Losses were -$25.32 million, 27.2% more than in 2024.
Financial StatementsNews
CapsoVision resumed with a Buy at Roth Capital
Roth Capital resumed coverage of CapsoVision (CV) with a Buy rating and $9 price target The company is developing advanced imaging and AI-integrated capsule endoscopy systems, the analyst tells invest...
Outlook CFO Lawrence Kenyon to step down, Kevin Lundquist to succeed
Outlook Therapeutics (OTLK) announced the appointment of Kevin Lundquist as CFO, effective September 1. Lundquist most recently served as CFO of CapsoVision (CV). In connection with Lundquist’s appoin...
CapsoVision initiated with a Buy at Titan Partners
Titan Partners analyst Kyle Bauser initiated coverage of CapsoVision (CV) with a Buy rating and $10 price target CapsoVision is a commercial-stage medical technology company developing proprietary cap...
CapsoVision files $250M mixed securities shelf
16:49 EDT CapsoVision (CV) files $250M mixed securities shelf
CapsoVision Earnings Call Transcript: Q2 2026
Q2 2026 saw 10% revenue growth and strong adoption of CapsoCam Plus, with over 176,000 patients imaged and a successful international launch of AI Highlights. Gross margin declined due to pricing and tariff pressures, but commercial momentum and pipeline progress remain strong.
CapsoVision Earnings release: Q2 2026
CapsoVision released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
CapsoVision Quarterly report: Q2 2026
CapsoVision has published its Q2 2026 quarterly earnings report on August 13, 2026.
CapsoVision Reports Second Quarter 2026 Financial Results
SARATOGA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions...
CapsoVision Registration statement: Registration filing
CapsoVision filed a registration statement on August 13, 2026, providing details about a securities offering with the SEC.
CapsoVision® Announces International Launch of AI Highlights
AI-assisted review feature designed to support physician review of small bowel capsule endoscopy studies using the CapsoCam Plus® system AI-assisted review feature designed to support physician review...
CapsoVision to Release Second Quarter 2026 Financial Results on August 13, 2026
SARATOGA, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions...
CapsoVision Appoints Gastroenterology Leader David S. Shields, M.D.
SARATOGA, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (Nasdaq: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions...
CapsoVision Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and reaffirmed governance commitments. All proposals passed, with final results to be filed in a Form 8-K. No shareholder questions were raised.
CapsoVision Earnings Call Transcript: Q1 2026
Revenue remained stable at $2.8M in Q1 2026, with strong utilization and expanding clinical adoption. AI-assisted capabilities are on track for mid-year launch, and a $14M private placement bolstered the balance sheet.
CapsoVision Earnings release: Q1 2026
CapsoVision released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
CapsoVision Quarterly report: Q1 2026
CapsoVision has published its Q1 2026 quarterly earnings report on May 14, 2026.
CapsoVision Reports First Quarter 2026 Financial Results
SARATOGA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions,...
CapsoVision to Release First Quarter 2026 Financial Results on May 14, 2026
SARATOGA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solution...
CapsoVision Proxy statement: Proxy filing
CapsoVision filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
CapsoVision files to sell 2.87M shares of common stock for holders
16:39 EDT CapsoVision (CV) files to sell 2.87M shares of common stock for holders
CapsoVision Registration statement: Registration filing
CapsoVision filed a registration statement on April 17, 2026, providing details about a securities offering with the SEC.
CapsoVision price target lowered to $10 from $14 at Benchmark
Benchmark analyst Bruce Jackson lowered the firm’s price target on CapsoVision (CV) to $10 from $14 and keeps a Speculative Buy rating on the shares after the company reported Q4…
CapsoVision Earnings Call Transcript: Q4 2025
Revenue grew 15% year-over-year in 2025, driven by CapsoCam Plus adoption and new account growth. AI-enabled product pipeline advanced, with pivotal studies and regulatory submissions on track. Balance sheet strengthened by $14 million equity raise.
CapsoVision Annual report: Q4 2025
CapsoVision has published its Q4 2025 annual report on March 26, 2026.
CapsoVision Earnings release: Q4 2025
CapsoVision released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.